Hank Yang
Obstetrics & Gynecology · Clovis, CANPI 1356429831
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by AstraZeneca at 41.7% of the total. Reporting peaked in 2019 at $3,290 and has fallen 83.2% since, to $552 in 2025. Among obstetrics & gynecology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $53.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Bristol Myers Squibb$2K
- GSK$359
- Takeda Pharmaceuticals U.S.A., Inc.$318
- Eisai Inc.$300
- Hologic Sales And Service, LLC$167
- plus $2K from 29 others
What the payments were for
- Consulting fees$4,49553%
- Food & beverage$4,02347%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $3,568 |
| Bristol Myers Squibb | 4 | $1,768 |
| GSK | 8 | $359 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $318 |
| Eisai Inc. | 15 | $300 |
| Hologic Sales And Service, LLC | 2 | $167 |
| Beigene USA, Inc. | 6 | $161 |
| Pfizer | 7 | $146 |
| Johnson & Johnson | 4 | $137 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $125 |
| Incyte Corporation | 5 | $116 |
| Stemline Therapeutics Inc. | 3 | $113 |
| Ipsen Biopharmaceuticals, Inc | 5 | $111 |
| Puma Biotechnology, Inc. | 4 | $109 |
| Beone Medicines USA, Inc. | 6 | $108 |
| AVEO Pharmaceuticals, Inc. | 4 | $102 |
| Array Biopharma Inc | 4 | $84 |
| Lilly USA, LLC | 4 | $79 |
| Syndax Pharmaceuticals, Inc. | 3 | $71 |
| Morphosys, US Inc. | 3 | $67 |
| Jazz Pharmaceuticals Inc. | 2 | $58 |
| Genentech USA, Inc. | 2 | $51 |
| Clovis Oncology, Inc. | 2 | $48 |
| Rigel Pharmaceuticals, Inc. | 2 | $45 |
| Mirati Therapeutics, Inc. | 2 | $45 |
| Gilead | 2 | $44 |
| EMD Serono, Inc. | 2 | $40 |
| ADC Therapeutics America, Inc. | 2 | $39 |
| Verastem, Inc. | 2 | $34 |
| Genmab U.S., Inc. | 1 | $30 |
| Taiho Oncology, Inc. | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Novocure Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Pharmaand GmbH | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$2,800
- IMBRUVICA$125
- ZEJULA$125
- JEMPERLI$117
- CoolSeal Generator$112
How this compares
$8,550 in reported general payments places this provider in the 95th percentile of 3,784 obstetrics & gynecology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 38 | $1,136 |
| Triamcinolone Acetonide | 13 | $153 |
| Lidocaine | 11 | $145 |
| Medroxyprogesterone Acetate | 12 | $143 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Clovis
- John SwansonClovis$60K
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
- Malcolm MunroLos Angeles$609K
- Michael KrychmanCosta Mesa$547K
- Anita NelsonTorrance$530K
- Jan SegnitzSan Jose$511K
- Risa KaganBerkeley$497K
- Michael GreenOxnard$424K
- Howard SalvaySanta Cruz$421K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.